Top

Published in:

13-03-2023 | Cystic Fibrosis | Review

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy

Authors: Giuseppe Cimino, Sara Sorrenti, Manuel Murciano, Paola Galoppi, Fiorentina Ascenzioni, Bruno Botta, Roberto Brunelli, On Behalf of the Sapienza University Working Group on Cystic Fibrosis in Pregnancy

Published in: Archives of Gynecology and Obstetrics | Issue 1/2024

Abstract

Introduction

Management of cystic fibrosis has recently stepped forward with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, although data on potential adverse effects are lacking for many categories of patients, such as pregnant women.

Methods

We report one of the first reports on the outcome of pregnancy in a woman treated with Elexacaftor/Tezacaftor/Ivacaftor during the second and third trimester of pregnancy, showing a significant improvement of respiratory status, compared with the first trimester when the medication was discontinued due to unknown and, therefore, potential teratogenic effects. Also, we performed the review of the existing literature on the topic.

Results

The course of pregnancy was uneventful, with reference to major obstetric complications, and the patient delivered a healthy neonate. These results were similar to those coming from other short series of pregnant women affected by cystic fibrosis and treated with CFTR modulators during pregnancy.

Conclusions

Thus, despite the lack of evidence on the topic, the use of Elexacaftor/Tezacaftor/Ivacaftor in pregnancy seems to be apparently not associated with major adverse events, thus opening optimistic scenarios in terms of management of these patients.

Shteinberg M, Haq IJ, Polineni D, Davies JC (2021) Cystic fibrosis. Lancet 397:2195–2211CrossRefPubMed

https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf (Accessed on 24 Oct 2021)

Riordan JR, Rommens JM, Kerem B et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922):1066–1073. https://doi.org/10.1126/science.2475911. (Erratum.In:Science1989;245:1437)CrossRefPubMed

Sueblinvong V, Whittaker LA (2007) Fertility and pregnancy: common concerns of the aging cystic fibrosis population. Clin Chest Med 28:433–443CrossRefPubMed

Gilljam M, Antoniou M, Shin J, Dupuis A, Corey M, Tullis DE (2000) Pregnancy in cystic fibrosis. Fetal and maternal outcome. Chest 118:85–91CrossRefPubMed

Barak A, Dulitzki M, Efrati O, Augarten A, Szeinberg A, Reichert N, Modan D, Weiss B, Miller M, Katzanelson D, Yahav Y (2005) Pregnancies and outcome in women with cystic fibrosis. Isr Med Assoc J 7(2):95–98 (PMID: 15729959)PubMed

Tan EK, Tan EL (2013) Alterations in physiology and anatomy during pregnancy. Best Pract Res Clin Obstet Gynaecol 27(6):791–802. https://doi.org/10.1016/j.bpobgyn.2013.08.001. (Epub 2013 Sep 4 PMID: 24012425)CrossRefPubMed

Davis PB (2011) Therapy for cystic fibrosis–the end of the beginning? N Engl J Med 365:1734–1735CrossRefPubMed

Hoy SM (2019) Elexacaftor/Ivacaftor/tezacaftor: first approval. Drugs 79:2001–2007CrossRefPubMed

10.

Zaher A, ElSaygh J, Elsori D, ElSaygh H, Sanni A (2021) A review of trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Cureus 13:e16144PubMedPubMedCentral

11.

Veit G, Roldan A, Hancock MA et al (2020) Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight 5:e139983CrossRefPubMedPubMedCentral

12.

Krasnowska EK, Pittaluga E, Brunati AM, Brunelli R, Costa G, De Spirito M, Serafino A, Ursini F, Parasassi T (2008) N-acetyl-l-cysteine fosters inactivation and transfer to endolysosomes of c-Src. Free Radic Biol Med 45(11):1566–1572. https://doi.org/10.1016/j.freeradbiomed.2008.09.012. (Epub 2008 Sep 23 PMID: 18845245)CrossRefPubMed

13.

Middleton PG, Mall MA, Dřevínek P et al (2019) Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381:1809–1819CrossRefPubMedPubMedCentral

14.

Heijerman HGM, McKone EF, Downey DG et al (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial [published correction appears in Lancet. 2020 May 30;395(10238):1694]. Lancet 394:1940–1948CrossRefPubMedPubMedCentral

15.

Trimble AT, Donaldson SH (2018) Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. J Cyst Fibros 17(2):e13–e16. https://doi.org/10.1016/j.jcf.2017.09.006. (Epub 2017 Oct 24 PMID: 29079142)CrossRefPubMed

16.

Vertex Pharmaceuticals Incorporated. Ivacaftor (Kalydeco) United States Prescribing Information. Available online: https://pi.vrtx.com/files/uspi_ivacaftor.pdf (accessed on 18 July 2020)

17.

Taylor-Cousar JL (2020) CFTR modulators: impact on fertility, pregnancy, and lactation in women with cystic fibrosis. J Clin Med 9:2706CrossRefPubMedPubMedCentral

18.

Jain R, Kazmerski TM, Zuckerwise LC, et al (2021) Pregnancy in cystic fibrosis: Review of the literature and expert recommendations [published online ahead of print, 2021 Aug 26]. J Cyst Fibros. https://doi.org/10.1016/j.jcf.2021.07.019

19.

Vekaria S, Popowicz N, White SW, Mulrennan S (2020) To be or not to be on CFTR modulators during pregnancy: risks to be considered. J Cyst Fibros 19(2):e7–e8. https://doi.org/10.1016/j.jcf.2019.12.004CrossRefPubMed

20.

Trimble A, McKinzie C, Terrell M, Stringer E, Esther CR Jr (2018) Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. J Cyst Fibros 17(6):779–782. https://doi.org/10.1016/j.jcf.2018.05.009CrossRefPubMedPubMedCentral

21.

Riccio M, Carnevale G, Cardinale V, Gibellini L, De Biasi S, Pisciotta A et al (2014) The Fas/Fas ligand apoptosis pathway underlies immunomodulatory properties of human biliary tree stem/progenitor cells. J Hepatol 61(5):1097–1105. https://doi.org/10.1016/j.jhep.2014.06.016. (Epub 2014 Jun 19 PMID: 24953023)CrossRefPubMed

22.

Mainz JG, Michl RK, Beiersdorf N, et al. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor. Schwangerschaft einer F508del homozygoten CF-Patientin mit fortgeschrittener Lungendestruktion unter Therapie mit lumacaftor/ivacaftor. Klin Padiatr. 2019;231(5):271–273. doi:https://doi.org/10.1055/a-0973-8565

23.

Ladores S, Kazmerski TM, Rowe SM (2017) A case report of pregnancy during use of targeted therapeutics for cystic fibrosis. J Obstet Gynecol Neonatal Nurs 46(1):72–77. https://doi.org/10.1016/j.jogn.2016.08.011CrossRefPubMed

24.

Kaminski R, Nazareth D (2016) A successful uncomplicated CF pregnancy while remaining on Ivacaftor. J Cyst Fibros 15(1):133–134. https://doi.org/10.1016/j.jcf.2015.11.013CrossRefPubMed

25.

Nash EF, Middleton PG, Taylor-Cousar JL (2020) Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators—an international survey. J Cyst Fibros 19(4):521–526. https://doi.org/10.1016/j.jcf.2020.02.018CrossRefPubMed

26.

Taylor-Cousar JL, Jain R (2021) Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros 20(3):402–406. https://doi.org/10.1016/j.jcf.2021.03.006CrossRefPubMed

27.

Kendle AM, Roekner JT, Santillana EC, Kis LE, Cain MA (2021) Cystic fibrosis transmembrane conductance regulator modulators during pregnancy: a case series. Cureus 13(8):e17427. https://doi.org/10.7759/cureus.17427CrossRefPubMedPubMedCentral

28.

Jain R, Taylor-Cousar JL (2021) Fertility, pregnancy and lactation considerations for women with CF in the CFTR modulator era. J Pers Med 11(5):418. https://doi.org/10.3390/jpm11050418CrossRefPubMedPubMedCentral

29.

Jain R, Wolf A, Molad M, Taylor-Cousar J, Jr CRE, Shteinberg M (2022) Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding. J Cyst Fibros 17:S1569-1993(22)01386-8

30.

Collins B, Fortner C, Cotey A, Esther CRJ, Trimble A (2022) Drug exposure to infants born to mothers taking elexacaftor, tezacaftor, and Ivacaftor. J Cyst Fibros 21(4):725–727CrossRefPubMed

31.

Murad MH, Asi N, Alsawas M, Alahdab F (2016) New evidence pyramid. Evid Based Med 21:125–127CrossRefPubMedPubMedCentral

32.

Heltshe SL, Godfrey EM, Josephy T, Aitken ML, Taylor-Cousar JL (2017) Pregnancy among cystic fibrosis women in the era of CFTR modulators. J Cyst Fibros 16:687–694CrossRefPubMedPubMedCentral

33.

Jain R, Magaret A, Vu PT et al (2022) Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design. BMJ Open Respir Res 9(1):e001289CrossRefPubMedPubMedCentral

Title: Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy
Authors: Giuseppe Cimino
Sara Sorrenti
Manuel Murciano
Paola Galoppi
Fiorentina Ascenzioni
Bruno Botta
Roberto Brunelli
On Behalf of the Sapienza University Working Group on Cystic Fibrosis in Pregnancy
Publication date: 13-03-2023
Publisher: Springer Berlin Heidelberg
Keywords: Cystic Fibrosis
Lactation
Cystic Fibrosis
Published in: Archives of Gynecology and Obstetrics / Issue 1/2024
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-023-06962-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Effect of obesity on the time to a successful medical abortion with misoprostol in first-trimester missed abortion

Diagnostic yield of copy number variation sequencing in fetuses with increased nuchal translucency: a retrospective study

Why don’t we follow influencers in obstetrics and gynaecology on Twitter to obtain information on the most recent international congresses?

Hysteroscopy-assisted suction curettage for early pregnancy loss: does it reduce retained products of conception and postoperative intrauterine adhesions?

Correction: Apical prolapse correction by unilateral pectineal suspension

Impact of progesterone on the immune system in women: a systematic literature review